CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be the first disclosed trispecific antibody for CStone, according to the company's website.

CStone Pharmaceuticals Co. Ltd. (HKEX:2616) will fund R&D up to completion of a Phase Ib trial and gains rights to the compound in China, including Hong Kong and Macau, Taiwan, South Korea and Singapore. Numab Therapeutics AG (Pfäffikon, Switzerland) retains rights elsewhere...